The abstract is read at the publisher; the summary is JClub's.
A quantitative immunofluorescence assay measured HER3, EGFR, and TROP2 protein across 329 HNSCC patients, with 100%, 97.5%, and 98.4% of cases above assay LOD.
- Why it matters: Head and neck cancer has limited quantitative target data for antibody-drug conjugates, making it hard to judge whether approved ADC targets are sufficiently expressed in this population.
- What they did: The study built a fluorescence assay for HER3 in formalin-fixed, paraffin-embedded tissues, converting signals to protein concentrations (amol/mm2) using cell lines calibrated by mass spectrometry.
- The result: HER3/EGFR, HER3/TROP2, and EGFR/TROP2 double-positivity reached 97.2%, 99.3%, and 98.6%, while HER2 double-positivity was much lower (34.2%, 34.6%, 30.5%), yet 39.1% showed HER2 above 52.5 amol/mm2.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.